Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind study of dapagliflozin added to glimepiride in type 2 diabetes with inadequate glycaemic control
2007-005931-27Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing dapagliflozin + glimepiride with placebo + glimepiride (2 arms). Primary endpoint: Change in HbA1c from baseline to week 24. Started Feb 2008; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-005931-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005931-27.